Carolina Barizan Perdão (1) 1. Crop Biolabs
It is known that embryonic tumors are often resistant to conventional treatments, such as chemotherapy cocktails, and have a poor prognosis. In addition to consequent long-term toxicity, as a result of high-dose treatment.
What is new is that nanomedicine and cell-based therapy have shown results to improve the prognosis and quality of life of children diagnosed with neuroblastoma (NB) and medulloblastoma (MB), the most common and aggressive tumors in childhood.
A paper published in 2022 by researchers from Spain, France, and Switzerland brought updates on advances in the treatment of embryonic tumors through nanotechnology and cellular therapies, discussing the key points behind preclinical studies and clinical trials of these advances.
According to the data collected, Nanomedicine and cell-based therapies have proven to be good alternatives to provide a safer way to carry anticancer drugs specifically to the tumor tissue. Among them, non-targeted and stimuli-responsive nanomedicines seem to hold the brightest prospects for MB and NB.
Access the full article: https://doi.org/10.1016/j.jconrel.2022.06.010
Learn more about Crop Biolabs’ services for cellular therapies: https://cropbiolabs.com.br/
